

An investigation into why people with kidney disease lose muscle and feel weak

Submission date 30/11/2015	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 10/02/2016	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 18/09/2023	Condition category Urological and Genital Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Chronic kidney disease (CKD) is a long-term condition where the kidneys do not work properly. In a healthy person, the kidneys are vital for filtering out the waste products and excess water in the blood, and converting them into urine. In patients suffering from CKD, the kidneys are unable to do this, and so the body is unable to get rid of the waste products building up in the blood. A common feature of CKD is muscle wasting (when the muscles waste away). This can start early on in the disease, and is thought to play an important role in the way the disease progresses, and even the patients' ultimate chance of survival. It inevitably leads to a poor quality of life and an inactive (sedentary) lifestyle, which in itself can be bad for general health. Currently, the exact cause of muscle wasting in CKD is not really known, and so further research is needed so that it can be better understood and treated. The aim of this study is to grow small pieces of muscle taken from the legs of adult CKD sufferers and healthy adults in the laboratory, in order to find out what is different in the muscle of CKD patients and what the cause of their muscle loss may be. These muscles will also be stretched in the lab to simulate exercise, in order to find out if exercise could have any positive effects.

Who can participate?

Adults suffering from severe CKD and healthy adults of the same age, sex and race.

What does the study involve?

All participants have a small sample of muscle tissue taken from their thigh (biopsy) using a needle. They also provide a blood sample and a urine sample at this time. Information about their condition is gathered using a questionnaire at the start of the study, and then again at 6, 12 and 24 months.

What are the possible benefits and risks of participating?

There are no direct benefits for participants taking part in this study. The muscle biopsy carries with it a small risk of bleeding and infection, but to minimise these risks participants taking blood thinners are not able to take part and the procedure will be performed under sterile conditions. The area will ache for a day or so afterwards.

Where is the study run from?
Leicester General Hospital (UK)

When is the study starting and how long is it expected to run for?
March 2015 to May 2016

Who is funding the study?
Kidney Research UK (UK)

Who is the main contact?
1. Dr Alice Smith (Scientific)
aa50@le.ac.uk
2. Dr Emma Watson (Scientific)
ec174@le.ac.uk

Contact information

Type(s)
Scientific

Contact name
Dr Alice Smith

ORCID ID
<https://orcid.org/0000-0002-9234-9060>

Contact details
Leicester Kidney Exercise Team
University of Leicester Academic Unit
Leicester General Hospital
Leicester
United Kingdom
LE5 5PW
+44 (0)1162 584346
aa50@le.ac.uk

Type(s)
Scientific

Contact name
Dr Emma Watson

ORCID ID
<https://orcid.org/0000-0002-3869-8972>

Contact details
Lab 117/119 MSB
University Road
University of Leicester
Leicester
United Kingdom

LE1 9HN
+44 (0)1162 525033
ec174@le.ac.uk

Additional identifiers

Integrated Research Application System (IRAS)
187619

Study information

Scientific Title

Mechanisms of muscle wasting in advanced chronic kidney disease

Acronym

Explore CKD

Study objectives

The aim of this study is to investigate the mechanisms of muscle wasting in human CKD and their potential to be manipulated by exercise.

Main research questions:

1. How is the molecular control of muscle protein synthesis and degradation modified in CKD and affected by exercise?
2. How is the process of myogenesis modified in CKD and affected by exercise?
3. Is there a molecular role of microRNA in muscle loss in CKD?

Ethics approval required

Old ethics approval format

Ethics approval(s)

NHS East Midlands - Leicester South Research Ethics Committee, 28/11/2015, ref: 15/EM/0467

Study design

Mechanistic observational laboratory-based study

Primary study design

Observational

Study type(s)

Other

Health condition(s) or problem(s) studied

Chronic kidney disease

Interventions

A one-off muscle sample will be collected from the leg of CKD patients and matched controls as well as a blood and urine sample. These samples will be used in laboratory experiments to understand the mechanisms of muscle loss in this disease. We will also collect clinical information at 6, 12 and 24 months.

Intervention Type

Other

Primary outcome(s)

Muscle fibre size is measured using immunohistochemistry.

Key secondary outcome(s)

1. Differences in the processes of myogenesis measured using flow cytometry, immunohistochemistry and PCR
2. Differences in protein turnover measured using uptake and release labelling experiments
3. MicroRNA expression and involvement in any dysregulation seen above measured using next generation sequencing and PCR
4. Amino acid transport and intracellular concentrations
5. Muscle architecture
6. Metabolic flexibility and mitochondrial function measured using high resolution respirometry at baseline, 6, 12 and 24 months
7. Differences in physical activity levels between groups determined using patient questionnaires at baseline, 6, 12 and 24 months

Completion date

02/11/2020

Eligibility

Key inclusion criteria

CKD patients:

1. Over 18 years of age
2. Diagnosed CKD stage 3b-5
3. If diabetic, good control - HbA1c <9%

Matched controls - will be matched to CKD patients for age, sex and race.

1. Over 18 years of age
2. Kidney function < 80mL/min/1.73m²
3. Good general health

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

73

Key exclusion criteria

CKD patients:

1. Aged under 18 years
2. Uncontrolled diabetes mellitus (HbA1c >9%)
3. Inability to give consent for any reason

Matched controls:

1. Aged under 18 years
2. Presence of CKD (eGFR>80mL/min/1.73m²)
3. Presence of other diseases known to cause muscle wasting (some cancers, sepsis, burns and HIV)
4. Inability to give informed consent for any reason.

Date of first enrolment

01/01/2015

Date of final enrolment

02/11/2020

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Leicester General Hospital

Gwendolen Road

Leicester

United Kingdom

LE5 4PW

Sponsor information

Organisation

University Hospitals of Leicester (UK)

ROR

<https://ror.org/02fha3693>

Funder(s)

Funder type

Charity

Funder Name

Kidney Research UK

Alternative Name(s)

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		25/04/2022	18/09/2023	Yes	No
Results article		06/12/2019	18/09/2023	Yes	No
Results article		14/01/2022	18/09/2023	Yes	No
HRA research summary			28/06/2023	No	No
Plain English results		18/09/2023	18/09/2023	No	Yes